Genetic alterations defining NSCLC subtypes and their therapeutic implications

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 179-189

  Pikor, Larissa A ^a,b   Ramnarine, Varune R ^a,b   Lam, Stephen ^a   Lam, Wan L ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Actionable alterations; Adenocarcinoma; CNA; Histological subtypes; Methylation; Personalized medicine; Sequencing; Squamous cell carcinoma

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; AP 26113; AZD 4547; B RAF KINASE; BEVACIZUMAB; BUPARLISIB; CABOZANTINIB; CH 5424802; CRIZOTINIB; DASATINIB; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GANETESPIB; GEFITINIB; K RAS PROTEIN; LDK 378; LENVATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NAVITOCLAX; NERATINIB; NILOTINIB; OSU 11274; PEMETREXED; PONATINIB; SELUMETINIB; SUNITINIB; TIVANTINIB; TRAMETINIB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VANDETANIB; XL 147;

CANCER SURVIVAL; CELL LINEAGE; CLINICAL PRACTICE; DNA METHYLATION; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC DIFFERENCE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVIEW; SMOKING; SQUAMOUS CELL CARCINOMA; THYROID CARCINOMA;

ACTIONABLE ALTERATIONS; ADENOCARCINOMA; CNA; HISTOLOGICAL SUBTYPES; METHYLATION; PERSONALIZED MEDICINE; SEQUENCING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84887015191     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.025     Document Type: Review

References (178)

1. Society, A.C. Cancer Facts & Figures 2012 2012.
2. Statistics, C.C.S.s.S.C.o.C. Canadian Cancer Statistics 2012 2012.
3. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
4. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C., et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, World Health Organization classification of tumours.
5. Mok T.S., Thongrasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
6. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
7. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
8. Righi L., Graziano P., Fornari A., Rossi G., Barbareschi M., Cavazza A., et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011, 117(15):3416-3423.
9. Warth A., Muley T., Herpel E., Meister M., Herth F.J., Schirmacher P., et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 2012, 61(6):1017-1025.
10. Garraway L.A., Sellers W.R. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2006, 6(8):593-602.
11. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450(7171):893-898.
12. Bass A.J., Watanabe H., Mermel C.H., Yu S.Y., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41(11). 1238-U105.
13. Bingle C.D. Thyroid transcription factor-1. Int J Biochem Cell Biol 1997, 29(12):1471-1473.
14. Ikeda K., Clark J.C., Shaw-White J.R., Stahlman M.T., Boutell C.J., Whitsett J.A. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem 1995, 270(14):8108-8114.
15. Que J., Luo X., Schwartz R.J., Hogan B.L. Multiple roles for Sox2 in the developing and adult mouse trachea. Development 2009, 136(11):1899-1907.
16. Wu M., Wang B., Gil J., Sabo E., Miller L., Gan L., et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 2003, 119(5):696-702.
17. Kargi A., Gurel D., Tuna B. The diagnostic value of TTF-1 CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007, 15(4):415-420.
18. Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012, 36(6):895-899.
19. Brcic L., Sherer C.K., Shuai Y., Hornick J.L., Chirieac L.R., Dacic S. Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2. Am J Clin Pathol 2012, 138(5):712-718.
20. Lockwood W.W., Chari R., Coe B.P., Thu K.L., Garnis C., Malloff C.A., et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 2010, 7(7).
21. Sun S., Schiller J.H., Gazdar A.F. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7(10):778-790.
22. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150(6):1121-1134.
23. Seo J.S., Ju Y.S., Lee W.C., Shin J.Y., Lee J.K., Bleazard T., et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012, 22(11):2109-2119.
24. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346.
25. An S.J., Chen Z.H., Su J., Zhang X.C., Zhong W.Z., Yang J.J., et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012, 7(6):e40109.
26. Thu K.L., Vucic E.A., Chari R., Zhang W., Lockwood W.W., English J.C., et al. Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PLoS One 2012, 7(3):e33003.
27. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001, 98(24):13790-13795.
28. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Thaesler Z., Pacyna-Gengelbach M., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001, 98(24):13784-13789.
29. McDoniels-Silvers A.L., Nimri C.F., Stoner G.D., Lubet R.A., You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002, 8(4):1127-1138.
30. McDoniels-Silvers A.L., Stoner G.D., Lubet R.A., You M. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 2002, 4(2):141-150.
31. Nacht M., Dracheva T., Gao Y., Fujii T., Chen Y., Player A., et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci USA 2001, 98(26):15203-15208.
32. Wilkerson M.D., Yin X., Hoadley K.A., Liu Y., Hayward M.C., Cabanski C.R., et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010, 16(19):4864-4875.
33. Hou J., Aerts J., den Hamer B., van Ijcken W., den Bakker M., Riegman P., et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010, 5(4):e10312.
34. Yamagata N., Shyr Y., Yanagisawa K., Edgerton M., Dang T.P., Gonzalez A., et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003, 9(13):4695-4704.
35. Virtanen C., Ishikawa Y., Honjoh D., Kimura M., Shimane M., Miyoshi T., et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002, 99(19):12357-12362.
36. Rohrbeck A., Neukirchen J., Rosskopf M., Pardillos G.G., Geddert H., Schwalen A., et al. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med 2008, 6:69.
37. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8(8):816-824.
38. Giordano T.J., Shedden K.A., Schwartz D.R., Kuick R., Taylor J.M.G., Lee N., et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001, 159(4):1231-1238.
39. Balsara B.R., Testa J.R. Chromosomal imbalances in human lung cancer. Oncogene 2002, 21(45):6877-6883.
40. Pei J., Balsara B.R., Li W., Litwin S., Gabrielson E., Feder M., et al. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 2001, 31(3):282-287.
41. Sy S.M., Wong N., Lee T.W., Tse G., Mok T.S., Fan B., et al. Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. Eur J Cancer 2004, 40(7):1082-1094.
42. Tonon G., Wong K.K., Maulik G., Brennan C., Feng B., Zhang Y., et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 2005, 102(27):9625-9630.
43. Yakut T., Schulten H.J., Demir A., Frank D., Danner B., Egeli U., et al. Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer 2006, 54(3):293-301.
44. Bjorkqvist A.M., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Tammilehto L., Mattson K., et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 1998, 22(1):79-82.
45. Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006, 118(6):1556-1564.
46. Luk C., Tsao M.S., Bayani J., Shepherd F., Squire J.A. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001, 125(2):87-99.
47. Massion P.P., Kuo W.L., Stokoe D., Olshen A.B., Treseler P.A., Chin K., et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002, 62(13):3636-3640.
48. Petersen I., Bujard M., Petersen S., Wolf G., Goeze A., Schwendel A., et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 1997, 57(12):2331-2335.
49. Staaf J., Isaksson S., Karlsson A., Jonsson M., Johansson L., Jonsson P., et al. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer 2012, 132(9):2020-2031.
50. Hammerman P.S., Lawrence M.S., Voet D., Jing R., Cibulskis K., Sivachenko A., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489(7417):519-525.
51. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
52. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150(6):1107-1120.
53. Liu J., Lee W., Jiang Z., Chen Z., Jhunjhunwala S., Haverty P.M., et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res 2012, 22(12):2315-2327.
54. Ju Y.S., Lee W.C., Shin J.Y., Lee S., Bleazard T., Won J.K., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012, 22(3):436-445.
55. Lee W., Jiang Z., Liu J., Haverty P.M., Guan Y., Stinson J., et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465(7297):7-473.
56. Liu P., Morrison C., Wang L., Xiong D., Vedell P., Cui P., et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012, 33(7):1270-1276.
57. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466(7308):73-869.
58. Baylin S.B. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc Am Thorac Soc 2012, 9(2):64-65.
59. Tessema M., Belinsky S.A. Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc 2008, 5(8):806-810.
60. Heller G., Zielinski C.C., Zochbauer-Muller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 2010, 29(1):95-107.
61. Shiraishi M., Sekiguchi A., Oates A.J., Terry M.J., Miyamoto Y. HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene 2002, 21(22):3659-3662.
62. Zochbauer-Muller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001, 61(1):249-255.
63. Toyooka S., Tokumo M., Shigematsu H., Matsuo K., Asano H., Tomii K., et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006, 66(3):5-1371.
64. Heller G., Babinsky V.N., Ziegler B., Weinzierl M., Noll C., Altenberger C., et al. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis 2012, 34(3):513-521.
65. Lockwood W.W., Wilson I.M., Coe B.P., Chari R., Pikor L.A., Thu K.L., et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One 2012, 7(5):e37775.
66. Selamat S.A., Chung B.S., Girard L., Zhang W., Zhang Y., Campan M., et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012, 22(7):211-1197.
67. Birney E., Stamatoyannopoulos J.A., Dutta A., Guigo R., Gingeras T.R., Margulies E.H., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447(7146):799-816.
68. Ponting C.P., Belgard T.G. Transcribed dark matter: meaning or myth?. Hum Mol Genet 2010, 19(R2):R162-R168.
69. Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., et al. The transcriptional landscape of the mammalian genome. Science 2005, 309(5740):1559-1563.
70. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866.
71. Lebanony D., Benjamin H., Gilad S., Ezagouri M., Dov A., Ashkenazi K., et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009, 27(12):7-2030.
72. Dacic S., Kelly L., Shuai Y., Nikiforova M.N. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol 2010, 23(12):82-1577.
73. Seike M., Goto A., Okano T., Bowman E.D., Schetter A.J., Horikawa I., et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009, 106(29):90-12085.
74. Tinzl M., Marberger M., Horvath S., Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004, 46(2):6-182. discussion 187.
75. Panzitt K., Tschernatsch M.M., Guelly C., Moustafa T., Stradner M., Strohmaier H.M., et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007, 132(1):42-330.
76. Ji P., Diederichs S., Wang W., Boing S., Metzger R., Schneider P.M., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22(39):41-8031.
77. Chari R., Thu K.L., Wilson I.M., Lockwood W.W., Lonergan K.M., Coe B.P., et al. Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 2010, 29(1):73-93.
78. Daraselia N., Wang Y., Budoff A., Lituev A., Potapova O., Vansant G., et al. Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res 2012, 2(1):93-103.
79. Gettinger S., Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med 2011, 32(4):51-839.
80. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11):91-2184.
81. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14(3):63-253.
82. Hanauske A.R., Eismann U., Oberschmidt O., Pospisil H., Hoffmann S., Hanauske-Abel H., et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007, 25(5):23-417.
83. Igawa S., Ryuge S., Wada M., Otani S., Maki S., Takakura A., et al. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy 2012, 58(4):20-313.
84. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107(7):96-1589.
85. Heist R.S., Engelman J.A. SnapShot: non-small cell lung cancer. Cancer Cell 2012, 21(3):448 e2.
86. Lovly C.M., Carbone D.P. Lung cancer in 2010: one size does not fit all. Nat Rev Clin Oncol 2011, 8(2):68-70.
87. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):80-175.
88. Pao W., Hutchinson K.E. Chipping away at the lung cancer genome. Nat Med 2012, 18(3):349-351.
89. Toyooka S., Mitsudomi T., Soh J., Aokage K., Yamane M., Oto T., et al. Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 2011, 59(8):37-527.
90. Shigematsu H., Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118(2):62-257.
91. Roberts P.J., Stinchcombe T.E. KRAS mutation: should we test for it, and does it matter?. J Clin Oncol 2013, 31(8):21-1112.
92. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14(12):6-1351.
93. Janne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14(1):38-47.
94. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23(1):8-121.
95. Heist R.S., Sequist L.V., Engelman J.A. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 2012, 7(5):33-924.
96. Narasimhan K., Pillay S., Bin Ahmad N.R., Bikadi Z., Hazai E., Yan L., et al. Identification of a polyoxometalate inhibitor of the DNA binding activity of Sox2. ACS Chem Biol 2011, 6(6):81-573.
97. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62(23):6997-7000.
98. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
99. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009, 9(8):563-575.
100. Drilon A., Rekhtman N., Ladanyi M., Paik P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol 2012, 13(10):e418-e426.
101. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009, 27(26):4232-4235.
102. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14(13):4275-4283.
103. Choi Y.L., Takeuchi K., Soda M., Inamura K., Togashi Y., Hatano S., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008, 68(13):4971-4976.
104. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
105. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
106. Wang R., Pan Y., Li C., Hu H., Zhang Y., Li H., et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012, 18(17):4725-4732.
107. Wang R., Hu H., Pan Y., Li Y., Ye T., Li C., et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012, 30(35):4352-4359.
108. Kohno T., Ichikawa H., Totoki Y., Yasuda K., Hiramoto M., Nammo T., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18(3):375-377.
109. Li F., Feng Y., Fang R., Fang Z., Xia J., Han X., et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 2012, 22(5):928-931.
110. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18(3):382-384.
111. Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S., et al. RET ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18(3):378-381.
112. Chao B.H., Briesewitz R., Villalona-Calero M.A. RET fusion genes in non-small-cell lung cancer. J Clin Oncol 2012, 30(35):4439-4441.
113. Sablin E.P. Kinesins and microtubules: their structures and motor mechanisms. Curr Opin Cell Biol 2000, 12(1):35-41.
114. Wells S.A., Gosnell J.E., Gagel R.F., Moley J., Pfister D., Sosa J.A., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28(5):767-772.
115. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18(5):1472-1482.
116. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4(120):120ra17.
117. Tartarone A., Lazzari C., Lerose R., Conteduca V., Improta G., Zupa A., et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer 2013, 81(3):328-336.
118. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28(33):4953-4960.
119. Huang M.H., Lee J.H., Chang Y.J., Tsai H.H., Lin Y.L., Lin A.M., et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol 2012, 7(1):112-120.
120. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
121. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10(11):760-774.
122. Lin L., Bivona T.G. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012, 2012:817297.
123. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75).
124. Oxnard G.R. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. Arch Pathol Lab Med 2012, 136(10):1205-1209.
125. Basak S.K., Veena M.S., Oh S., Huang G., Srivatsan E., Huang M., et al. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One 2009, 4(6):e5884.
126. Yeo C.D., Kim J.W., Kim K.H., Ha J.H., Rhee C.K., Kim S.J., et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer 2013, 81(2):207-212.
127. Masago K., Togashi Y., Fukudo M., Terada T., Irisa K., Sakamori Y., et al. Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. Clin Lung Cancer 2011, 12(5):307-312.
128. Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012, 2(9):798-811.
129. Peifer M., Fernandez-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44(10):1104-1110.
130. Wistuba I.I., Gazdar A.F., Minna J.D. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001, 28(2 Suppl. 4):3-13.
131. Kim E.S., Herbst R.S., Wistuba I.I., Lee J.J., Blumenschein G.R., Tsao A., et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1(1):44-53.
132. Kris M.G., Lau C.Y., Ang D., Brzostowski E., Riely G.J., Rusch V.W., et al. Initial results of LC-MAP: an institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma. 2010 ASCO Annual Meeting 2010.
133. Paik P.K., Hasanovic A., Wang L., Rekhtman N., Ladanyi M., Kris M.G. Multiplex testing for driver mutations in squamous cell carcinomas of the lung. 2012 ASCO Annual Meeting 2012.
134. Wagle N., Berger M.F., Davis M.J., Blumenstiel B., Defelice M., Pochanard P., et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012, 2(1):82-93.
135. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
136. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
137. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
138. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39(Database issue):D945-D950.
139. Emery C.M., Vijayendran K.G., Zipser M.C., Sawyer A.M., Niu L., Kim J.J., et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009, 106(48):20411-20416.
140. Marks J.L., Gong Y., Chitale D., Golas B., McLellan M.D., Kasai Y., et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008, 68(14):5524-5528.
141. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
142. Takeuchi K., Choi Y.L., Soda M., Inamura K., Togashi Y., Hatano S., et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008, 14(20):6618-6624.
143. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15(9):3143-3149.
144. Bergethon K., Shaw A.T., Ou S.H., Katayama R., Lovly C.M., McDonald N.T., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30(8):863-870.
145. Janne P.A., Meyerson M. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol 2012, 30(8):878-879.
146. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131(6):1190-1203.
147. Suehara Y., Arcila M.E., Wang L., Hasanovic A., Ang D.C., Ito T., et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012, 18(24):6599-6608.
148. Rimkunas V.M., Crosby K.E., Li D., Hu Y., Kelly M.E., Gu T.L., et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012, 18(16):4449-4457.
149. Clinical Trials Registry and Database 2013, [cited 2013; Available from: http://clinicaltrials.gov].
150. Matsubara D., Kanai Y., Ishikawa S., Ohara S., Yoshimoto T., Sakatani T., et al. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol 2012, 7(12):1872-1876.
151. Ramos A.H., Dutt A., Mermel C., Perner S., Cho J., Lafargue C.J., et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009, 8(21):2042-2050.
152. Kim H.S., Mitsudomi T., Soo R.A., Cho B.C. Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 2013, 80(3):249-255.
153. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2(62).
154. Heist R.S., Mino-Kenudson M., Sequist L.V., Tammireddy S., Morrissey L., Christiani D.C. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012, 7(12):1775-1780.
155. Dutt A., Ramos A.H., Hammerman P.S., Mermel C., Cho J., Sharifnia T., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011, 6(6):e20351.
156. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008, 105(36):13568-13573.
157. Kim Y.R., Oh J.E., Kim M.S., Kang M.R., Park S.W., Han J.Y., et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010, 220(4):446-451.
158. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006, 3(10):e420.
159. Singh A., Bodas M., Wakabayashi N., Bunz F., Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010, 13(11):1627-1637.
160. Johnson F.M., Bekele B.N., Feng L., Wistuba I., Tang X.M., Tran H.T., et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(30):4609-4615.
161. Day E., Waters B., Spiegel K., Alnadaf T., Manley P.W., Buchdunger E., et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599(1-3):44-53.
162. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., Dutt A., Zhou W., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1(1):78-89.
163. Perez-Moreno P., Brambilla E., Thomas R., Soria J.C. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012, 18(9):2443-2451.
164. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448(7152):439-444.
165. Ikenoue T., Kanai F., Hikiba Y., Obata T., Tanaka Y., Imamura J., et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005, 65(11):4562-4567.
166. Kang S., Bader A.G., Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005, 102(3):802-807.
167. Yamamoto H., Shigematsu H., Nomura M., Lockwood W.W., Sato M., Okumura N., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68(17):6913-6921.
168. Naoki K., Chen T.H., Richards W.G., Sugarbaker D.J., Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62(23):7001-7003.
169. Leicht D.T., Balan V., Kaplun A., Singh-Gupta V., Kaplun L., Dobson M., et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007, 1773(8):1196-1212.
170. Kohno T., Takahashi M., Manda R., Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998, 22(2):152-156.
171. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36(7):768-776.
172. Jin G., Kim M.J., Jeon H.S., Choi J.E., Kim D.S., Lee E.B., et al. PTEN mutations and relationship to EGFR, ERBB2 KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010, 69(3):279-283.
173. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65(4):1479-1488.
174. Onozato R., Kosaka T., Kuwano H., Sekido Y., Yatabe Y., Mitsudomi T., et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009, 4(1):5-11.
175. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007, 67(5):2081-2088.
176. Kong-Beltran M., Seshagiri S., Zha J., Zhu W., Bhawe K., Mendoza N., et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006, 66(1):283-289.
177. Koivunen J.P., Kim J., Lee J., Rogers A.M., Park J.O., Zhao X., et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 2008, 99(2):245-252.
178. Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448(7155):807-810.